WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. PSDV today announced that its licensee Alimera Sciences has entered into
labeling discussions with the U.S. Food and Drug Administration (FDA)
for ILUVIEN® for Diabetic Macular Edema (DME) and, as a result, reported
its agreement with the FDA that the January 2014 Dermatologic and
Ophthalmic Advisory Committee meeting to discuss ILUVIEN for DME was no
longer necessary.
Alimera reported that it plans to respond to the FDA's October 2013
Complete Response Letter (CRL) in the first quarter of 2014 and intends
to address the concerns raised regarding the facility at which ILUVIEN
for DME is
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in